Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...

Find out how antiplatelet therapy compares to anticoagulation after TAVI—keep reading for clinical implications and guidance.

In-hospital Outcomes of Simultaneous and Staged Transcatheter Aortic Valve Replacement and Endovascular Aneurysm Repair: An Analysis of the National Inpatient Sample 2018-2021 ...

Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve ...

Progress with transcatheter tricuspid valve replacement (TTVR) candidate devices Topaz, LuX-Valve Plus, VDyne, and Trisol for severe to torrential TR was shared at the EuroPCR meeting in Paris ...

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular calcification at high surgical risk for open-heart surgery or ineligible ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter aortic valve replacement (TAVR) had similar rates of death or disabling ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the ...

Sucosky's groundbreaking research on bicuspid aortic valve disease has garnered attention not only from the American Heart Association but also from his colleagues at KSU.

TCT 131: In-Hospital, 1-Year and Long-Term Outcomes of Transcatheter Aortic Valve Replacement in Patients Requiring Permanent Pacemaker Implantation Receive the the latest news, research, and ...